Values First Advisors Inc. Has $484,000 Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Values First Advisors Inc. cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,906 shares of the specialty pharmaceutical company’s stock after selling 1,506 shares during the period. Values First Advisors Inc. owned about 0.05% of Collegium Pharmaceutical worth $484,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Victory Capital Management Inc. grew its position in Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after acquiring an additional 215,874 shares during the last quarter. Emerald Advisers LLC grew its holdings in shares of Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after buying an additional 175,892 shares during the period. Emerald Mutual Fund Advisers Trust raised its holdings in Collegium Pharmaceutical by 24.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock valued at $25,591,000 after buying an additional 131,835 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Collegium Pharmaceutical during the 3rd quarter worth approximately $4,693,000.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on COLL. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Friday, January 10th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Trading Down 3.3 %

COLL opened at $30.53 on Thursday. Collegium Pharmaceutical, Inc. has a twelve month low of $28.39 and a twelve month high of $42.29. The company has a fifty day moving average of $31.03 and a 200-day moving average of $34.01. The stock has a market cap of $984.59 million, a PE ratio of 13.16 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.